Lars Johansson (CSO at Antaros Medical) has been invited later this week at the Metabolic multi Organ Science Accelerating Innovation in Clinical trials (MOSAiC) forum. Lars will be discussing how to embed cardiovascular, kidney, and metabolism (CKM) imaging sub-studies in MASLD/MASH clinical trials, before then taking part in the MOSAiC Multi-Stakeholder Think Tank Moderated debate on Practical Feasibility of Ancillary Studies.
While all linked, chronic liver diseases like metabolic dysfunction-associated steatohepatitis (MASH) have different disease trajectories and progression patterns than other metabolic diseases like heart failure or chronic kidney disease (CKD). This means that in order to successfully include imaging sub-studies for cardiac, kidney, and other metabolic diseases in a MASLD/MASH clinical trial, it is crucial to both include the right patient population and to utilise the right biomarkers and endpoints.
To hear more, catch Lars’ talk at the MOSAIC forum.
Title: CKM bioimaging sub-studies
Session: Embedding CKM sub-studies in MASLD/MASH trials and MASLD/MASH sub-studies in CKM trials
Thursday, October 24 15:30-17:40 EDT
See the full program here.
About MOSAiC
MOSAiC is a global NASH/MASH trialist forum that brings together cardiology, endocrinology, and hepatology clinical trialists with industry, regulatory experts, payers, patient representatives and other stakeholders to further advance collective intelligence and foster collaboration about clinical trials through cross-talks.
This year the MOSAiC forum takes place from October 24-25 at the French Embassy in Washington D.C.